Vadastuximab is a novel antibody-drug compound representing a important advancement in the approach of acute myeloid leukemia (AML). This innovative therapy specifically targets CD33, a antigen frequently https://ztndz.com/story28236658/vadastuximab-a-deep-examination-into-cd33-specific-therapy